SCHEMBL30869094

SCHEMBL30869094

CC(C)(C)OC(=O)N(CCC=O)Cc1ccc(OC(F)(F)F)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 5/20 0.38
ROCK2 O75116 1/20 0.37
PPARD Q03181 2/20 0.35
PPARA Q07869 2/20 0.35
PPARG P37231 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MITF O75030 1/20 0.34
HTT P42858 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
SCN9A Q15858 2/20 0.34
SCN1A P35498 1/20 0.34
KCNH2 Q12809 1/20 0.34
SCN5A Q14524 1/20 0.34
SCN2A Q99250 1/20 0.34
SCN8A Q9UQD0 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27321821 0.94 SCN3A (0.37) SCN3AROCK2PPARDPPARAPPARG
SCHEMBL30803621 0.88 SCN3A (0.37) SCN3AROCK2ALDH1A1KDM4EMITF
SCHEMBL30869138 0.86 SSTR4 (0.39) SCN3AROCK2PPARDPPARAPPARG
SCHEMBL27371903 0.86 SCN3A (0.40) SCN3AROCK2PPARDPPARAPPARG
SCHEMBL27377441 0.86 L3MBTL1 (0.38) SCN3AROCK2PPARDPPARAPPARG
SCHEMBL26049694 0.85 CA14 (0.40) SCN3AROCK2PPARDPPARAPPARG
SCHEMBL30694800 0.85 CA14 (0.40) SCN3AROCK2PPARDPPARAPPARG
SCHEMBL29900268 0.84 SCN3A (0.39) SCN3AROCK2PPARDPPARAPPARG
SCHEMBL30803437 0.84 SCN3A (0.37) SCN3AROCK2PPARDPPARAPPARG
SCHEMBL26048981 0.84 SCN3A (0.39) SCN3AROCK2PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTPR LTD (GB) 2026-03-26 US disclosed
EP-4584249-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS Cambridge Enterprise Limited (GB) 2025-07-16 EP disclosed
WO-2024052702-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CSNK1A1, CSNK1G1, CSNK2A3 SCN3A 209/4885ROCK2 2190/4885PPARD 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.